Adult & Pediatric Asthma

1. Challenges of living with asthma: Results of a survey conducted using mobile application among asthmatics in India (ERS 2024) 2. Extent and impact of SABA inhaler overuse among asthma patients in India (ERS 2023) Asthma - management, Bronchodilators, Exacerbation 3. Burden of Small Airways Dysfunction (SAD) Asthma defined by Oscillometry and Spirometry among 1334 Asthmatics across 5 Centres in India (NAPCON Coimbatore 2024, NAPCON Pune 2025 and ERS 2024). 4. Phenotypic Differences Between Asthmatics with and without Small Airways Dysfunction (SAD) as Defined by Lung Oscillometry and Spirometry (NAPCON Coimbatore 2024, NAPCON Pune 2025 and ERS 2024). 5. Trends in the Management of Mild Asthma in India: Results of the TRACE survey. (NAPCON Delhi 2023, NAPCON Hyderabad 2023, APICON Delhi 2024 and ERS 2025) 6. Survey to understand physicians’ practice patterns for asthma management in India- TracAsthma Survey (NAPCON Jaipur 2025) 7. Prescription Patterns and trends IN the use of ICS-LABA Combinations in Indian children with asthma: The RAINBOW survey (Respicon 2024) 8. Exploring the Pattern and Preferences of Anti-Inflammatory Reliever in Asthma Management Across India (NAPCON Coimbatore 2024, ERS 2025, NAPCON Pune 2025) 9. Uncontrolled asthmatics with small airways dysfunction (SAD) and response to extra-fine ICS/LABA formulation: A real-world, observational, effectiveness, multi-centre study from India (ERS 2025) 10. Understanding Perceptions and Place of Triple Therapy for Asthma Management: The ESCALATE Survey (ERS 2025; NAPCON Jaipur 2025) 11. Understanding the Educational Needs, Preferences and Challenges of People with Chronic Respiratory Disease: ENRICH Survey (NAPCON Jaipur 2025) 12. Digital Interventions for Integrated Care of OAD Patients in India: DECODE Survey (ERS 2025 and NAPCON Jaipur 2025) 13. Insights from the ARISE survey: Current Approaches in the Treatment of Allergic Rhinitis Patients with Coexistent Asthma in India 14. SAFETY AND EFFECTIVENESS OF FLUTICASONE FUROATE/VILANTEROL DPI IN ASTHMA: RESULTS OF A 12-WEEK POST MARKETING SURVEILANCE (PMS) IN INDIA